For Healthcare Professionals

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)


About the study

The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via intravenous (IV) administration in adult and pediatric participants with GSD1a.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Documented GSD1a with confirmation by genetic testing
  2. Documented history of ≥1 hypoglycemic event with blood glucose <60 mg/dL (<3.3 mmol/L) and symptoms of hypoglycemia in the absence of acute illness, with at least one such event in the 4 weeks before starting run in (Day -14)


Exclusion Criteria:

  1. Liver transplant, including hepatocyte cell therapy/transplant
  2. Received gene therapy for GSD1a
  3. Presence of liver adenoma >5 centimeters (cm) (±10%) in size
  4. Participant has a diagnosis of type 1 or type 2 diabetes mellitus
  5. Presence of liver adenoma with growth of >2 cm or >5 newly diagnosed liver adenomas, in the previous 2 years
  6. Participants with known allergy to magnetic resonance imaging (MRI) contrast can be enrolled and receive MRI without contrast. Participants for whom MRI is contraindicated could be enrolled if an alternative imaging technique can be performed.

Note: Additional inclusion/exclusion criteria may apply, per protocol.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Glycogen Storage Disease

Age (in years)



Phase 1

Participants needed


Est. Completion Date

Oct 21, 2025

Treatment type



ModernaTX, Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.